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TRPV3 was cloned from keratinocytes
and described as a thermosensitive
member of the transient receptor
potential ion channel family. Although
its role in thermosensation is currently
under debate, it is highly expressed in
the epidermis and functions as a
nonselective, Ca2þ-permeable cation
channel (Huang et al., 2011; Nilius and
Bı´ro´ 2013; Peier et al., 2002). Despite
its high abundance in the skin, its
genetic deletion causes only moderate,
often strain- or sex-dependent, cuta-
neous phenotypic modifications, such
as formation of curly whiskers and
wavy hair, defect in epidermal barrier
functions, and alterations in epidermal
nitrate homeostasis (Cheng et al., 2010;
Miyamoto et al., 2011). In contrast,
gain-of-function mutations of TRPV3
result in dramatic cutaneous alterations
associated with severely dry skin,
dermatitis, and hairless phenotype in
both mice and rats (Asakawa et al.,
2006; Xiao et al., 2008). Moreover,
similar gain-of-function mutations of
TRPV3 were found to play an etiolog-
ical role in a rare human genoderma-
tosis, Olmsted syndrome, characterized
by periorificial hyperkeratosis, hypo-
trichosis, alopecia, and severe pruritus
(He et al., 2015; Lin et al., 2012; Ni
et al., 2016). Encouraged by these
findings, we verified the role of TRPV3
in human hair growth control by
inducing catagen in mechanistic
studies (Borbı´ro´ et al., 2011) and, most
recently, we also described the proin-
flammatory action of TRPV3 activation
in human epidermal keratinocytes
(Szo¨ll}osi et al., 2018), whereas others
reported its role in dry skin-associatedAbbreviations: AA, arachidonic acid; SG, sebaceous
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ever, the extended inflammatory
symptoms and the disrupted lipid bar-
rier found both in rodents and humans
suggested that TRPV3-expressing skin
cells other than keratinocytes might
also be involved in the development of
inflammatory skin conditions induced
by TRPV3 hyperfunction. Therefore, in
this study, we investigated the expres-
sion and activation of TRPV3 in human
sebocytes, which are important regula-
tors of cutaneous homeostasis (To´th
et al., 2011).
Immunohistochemical analysis
showed that, like epidermal keratino-
cytes, human sebaceous glands (SG)
express TRPV3 in situ (Figure 1a).
Peripheral undifferentiated cells show
stronger immunopositivity than cen-
trally located terminally differentiated
cells. We also showed the presence of
TRPV3 protein and mRNA transcripts in
human SG-derived SZ95 sebocytes
(Zouboulis et al., 1999), a widely
accepted model cell line to study SG
biology in vitro (Figure 1bed). We
observed that TRPV3 expression is
decreased in post-confluent, more
differentiated cultures compared with
the highly proliferating pre-confluent
cultures (Figure 1c and d). The syn-
thetic TRPV3 activator 2-APB, as well
as the plant-derived carvacrol, evoked
marked elevation of the intracellular
Ca2þ concentration (Figure 1e), sug-
gesting that TRPV3 is, indeed, func-
tionally expressed in human sebocytes.
The evoked Ca2þ signals were practi-
cally abolished in the presence of the
general TRP channel blocker ruthenium
red but were not affected by either
AMG9810 or HC067047, selectivegland; siRNA, small interfering RNA
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e 139antagonists of the closely related
channels TRPV1 and TRPV4, respec-
tively (Figure 1f), channels that are also
functionally expressed by sebocytes
(Ola´h et al., 2014; To´th et al., 2009).
Because highly specific TRPV3 activa-
tors and inhibitors are not available
commercially, we then investigated the
effect of RNA interference-based
silencing of TRPV3 expression on
Ca2þ signals. Transfection of the sebo-
cytes with small interfering RNA
(siRNA) targeting TRPV3 resulted in a
partial, yet marked decrease of the
channel expression (see Supplementary
Figure S1 online) compared with the
scrambled RNA-transfected cells, and
significantly suppressed the amplitude
and the rate of rise of the agonist-
evoked Ca2þ signals (Figure 1g and h);
these data provided strong evidence for
the activation of TRPV3 by the applied
compounds. Higher concentrations of
the activators reduced the living cell
number in 24 hours, but lower con-
centrations (still able to evoke Ca2þ
signals) did not influence the viability
of sebocytes (see Supplementary
Figure S2 online), confirming previous
results on Ca2þ signaling-induced
sebocyte apoptosis (Zouboulis et al.,
2017).
Because sebaceous lipids essentially
contribute to the epidermal barrier
functions, we also investigated the in-
fluence of TRPV3 on lipid synthesis in
SZ95 cells. Activation of TRPV3 with
non-cytotoxic concentrations of 2-APB
and carvacrol decreased lipid synthe-
sis during arachidonic acid (AA)-
induced differentiation of scrambled
RNA-transfected cells used as control.
TRPV3 agonists were less effective at
suppressing AA-induced lipid synthesis
in cells transfected with siRNA target-
ing TRPV3 (Figure 2a). Moreover, AA
was slightly but significantly more
effective in TRPV3-silenced cells,
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Figure 1. Human sebocytes express functional TRPV3 ion channels. (a) Immunohistochemical staining
of TRPV3 (3,30-diaminobenzidine, brown precipitate) on human SGs and epidermis. White and yellow
arrowheads indicate undifferentiated and terminally differentiated cells, respectively. Scale bars ¼
50 mm. (b) Immunocytochemical staining of TRPV3 (FITC, green fluorescence) on SZ95 sebocytes. Blue
indicates nuclei (DAPI). Scale bar ¼ 25 mm. (c) Western blot analysis of protein lysates of human
epidermal keratinocytes and SZ95 sebocytes from pre- and post-confluent (pre and post, respectively)
cultures followed by immunolabeling with anti-TRPV3 antibody. Molecular weights in kDa are indicated.
Expected molecular weight of recombinant TRPV3 is approximately 91 kDa (UniProt ID: Q2M3L1;
UniProt, 2006). Multiple bands may refer to uncharacterized posttranslational modifications (e.g.,
glycosylation) and multimerization of channel subunits. (d) Relative expression of TRPV3 transcripts in
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TRPV3 on sebocytessuggesting that basal activity of TRPV3
also negatively regulates AA-induced
lipid synthesis. The effect of TRPV3
agonists was not restricted to AA-
induced lipid synthesis: they also
inhibited the lipogenic effect of the
endocannabinoid anandamide and of
the combination of linoleic acid and
testosterone; and they slightly
decreased basal lipid synthesis of non-
transfected sebocytes, as well (see
Supplementary Figure S3 online).
Moreover, carvacrol did not induce
cellular differentiation because it did
not affect cellular granulation either
under control conditions or in AA-
treated cells. However, carvacrol
selectively inhibited the AA-induced
accumulation of cellular lipids, the
effect of which was prevented by
ruthenium red, indicating that indeed
TRPV3 mediates the effect (see
Supplementary Figure S4a online).
Simultaneously, carvacrol down-
regulated PPAR-g and NRIP1, impor-
tant positive regulators of sebaceous
lipid synthesis (Dozsa et al., 2014; Ola´h
et al., 2014). These results suggest that
TRPV3-mediated Ca2þ signaling gener-
ally inhibits lipid synthesis of sebocytes
independently of the activated lipogenic
pathways, confirming a recent study of
our group on the role of Ca2þ signaling
in human sebocytes using another=
pre- and post-confluent SZ95 sebocyte cultures.
(e) Representative Ca2þ signals on SZ95 sebocytes
evoked by TRPV3 agonists 2-APB and carvacrol
in the presence or absence of ruthenium red,
applied as indicated. (f) Statistical analysis of
the amplitudes of the Ca2þ signals in various
conditions as indicated. n ¼ 6 in each group.
***P < 0.001 compared with the control and
###P < 0.001 between the indicated groups as
determined by analysis of variance and Bonferroni
post hoc test. (g) Representative Ca2þ signals
evoked by TRPV3 agonists 2-APB (200 mmol/L)
and carvacrol (500 mmol/L) on human SZ95
sebocytes transfected with scrambled RNA
(scrRNA) or siRNA targeting TRPV3 (siRNA-
TRPV3). (h) Statistical analysis on the amplitude
and the rate of rise of the 2-APBe and carvacrol-
induced Ca2þ signals in sebocytes transfected
with scrambled or siRNA targeting TRPV3, as
indicated. n ¼ 5 in each group. þP < 0.05 and
þþP < 0.01 between the indicated groups, as
determined by two-tailed Student t test for
independent samples. KC, human epidermal
keratinocyte; mM, mmol/L; Max., maximal;
MW, molecular weight; NC, negative control;
RR, ruthenium red; scr, scramble; SG, sebaceous
gland; siRNA, small interfering RNA.
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Figure 2. Activation of TRPV3 inhibits lipid synthesis associated with sebaceous differentiation and induces the synthesis and release of proinflammatory
cytokines. (a) Quantitative Nile Red staining of neutral lipids in scrambled RNA (scr RNA) and TRPV3-targeting siRNA (siRNA-TRPV3) transfected SZ95
sebocytes treated with arachidonic acid and TRPV3 agonists for 24 hours, as indicated. n  4 in each group. ***P < 0.001 between the indicated groups as
determined by one-way analysis of variance and Bonferroni post hoc test. (b) Relative expression of proinflammatory cytokine transcripts in SZ95 sebocytes after
a 6-hourelong treatment with vehicle (used as control) or TRPV3 agonists, as indicated. #P < 0.05 and ###P < 0.001 compared with the vehicle-treated control
using one-way analysis of variance and Dunnett post hoc test. PPIA used as endogenous control reference gene. (c) Carvacrol (500 mmol/L, 6 hours) induced
changes in relative expression of proinflammatory cytokine genes (determined by quantitative PCR) in scrambled RNA (scr RNA) and TRPV3-specific siRNA
(siRNA-TRPV3) transfected SZ95 sebocytes. (d) Release of proinflammatory cytokines (determined from supernatants using ELISA) after the same treatments as
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TRPV3 on sebocytesexperimental setting (Zouboulis et al.,
2017). Our data are consistent with
our previous findings because TRPV1
and TRPV4 activation by capsaicin and
cannabidiol, respectively, inhibited
sebaceous lipid synthesis (Ola´h et al.,
2014; To´th et al., 2009).
Beyond lipid synthesis, SGs play an
important role in the regulation of
cutaneous immune functions (To´th
et al., 2011). Therefore, we also
assessed the effect of TRPV3 activation
on cytokine expression of SZ95 sebo-
cytes. Our findings showed that tran-
scription of several proinflammatory
cytokines was unambiguously triggered
by the TRPV3 agonist carvacrol within 6
hours (Figure 2b), although during this
time, 2-APB was ineffective. To assess
the TRPV3 specificity of the carvacrol
treatment, we repeated the experiments
on TRPV3-silenced SZ95 sebocytes. In
this condition, we found a reduced ef-
fect of the activator compared with
scrambled RNA-transfected cells
(Figure 2c), again arguing for the
involvement of TRPV3 in mediating the
effect of carvacrol. Moreover, we found
that not only the expression but also the
release of some proinflammatory cyto-
kines was decreased by TRPV3-specific
RNA interference in carvacrol-treated
sebocytes (Figure 2c).
Taken together, our findings suggest
that sebocytes might be involved in the
pathogenesis of dry skin-associated in-
flammatory dermatoses linked to
TRPV3 hyperactivity. Furthermore, our
preclinical findings introduce TRPV3 as
a previously unreported negative regu-
lator of sebaceous lipid synthesis with a
marked proinflammatory effect. Further
clinical studies are urged to assess the
clinical efficacy of TRPV3 inhibitors on
the therapeutic management of certain
inflammatory skin conditions.
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